Sign In
Buy MBRX
$0.400
-0.620 (-60.78%)
At Close: Jul 31, 2026
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
09:45am, Thursday, 25'th Apr 2024
Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2024 / JTC Team ("JTC"), a ful
PRISM MarketView – Biotech Breakfast
07:00am, Monday, 22'nd Apr 2024
Roche's Alecensa Gets FDA Green Light; ImmunityBio Gains as PDUFA Date Approaches for Bladder Cancer Drug; Key Drug Trial Failures in 2024 New York, N.Y., April 22, 2024 – PRISM MarketView – Heal
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
08:30am, Thursday, 18'th Apr 2024
– Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
08:30am, Wednesday, 10'th Apr 2024
Annamycin demonstrated to be a more potent inhibitor of topoisomerase II-alpha and II-beta while remaining inactive against established cardiomyocyte cultures Results clearly aligned with lack of drug
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
10:45am, Thursday, 28'th Mar 2024
Live webcast on Thursday, April 4 th at 4:10 PM ET HOUSTON, March 28, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
09:25am, Wednesday, 27'th Mar 2024
Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Thursday, March 28 th at 12:00 PM ET HOUSTON , March 27, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Molecul
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
09:05am, Wednesday, 27'th Mar 2024
Patent, once issued, will provide composition of matter protection through 2040, with potential for additional term extension Next-generation anthracycline uses unique lipid-based delivery technology
Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript
11:25am, Monday, 25'th Mar 2024
Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
07:30am, Monday, 25'th Mar 2024
– Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 60% (50% CR) in 2nd line AML subjects – AnnAraC has potential to fill significant unmet need and expected
Moleculin Reports Full Year 2023 Financial Results
04:05pm, Friday, 22'nd Mar 2024
– Year marked by growing body of positive Annamycin efficacy and safety clinical data expected to support advancement into a pivotal study for AML – Company to host conference call and web
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
07:30am, Wednesday, 20'th Mar 2024
In-depth discussion of stratification of Company's 2nd line data of Annamycin as a therapy for acute myeloid leukemia (AML) Guidance to be provided for clinical development strategy for advancement of
Moleculin to Present at the 36th Annual ROTH Conference
09:05am, Tuesday, 12'th Mar 2024
Live webcast fireside chat on Monday, March 18 th at 9:00 AM PT HOUSTON , March 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmace
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
12:02pm, Tuesday, 14'th Nov 2023
Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.
Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
08:45am, Tuesday, 07'th Nov 2023
HOUSTON , Nov. 7, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinic
Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up
09:01am, Friday, 22'nd Sep 2023
Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.
